Sylvester Comprehensive Cancer Center

Articles

Sylvester’s Researchers Lead Major Treatment Overhauls For Acute Myeloid Leukemia

December 5th 2025

Researchers at Sylvester Comprehensive Cancer Center lead the way in innovative AML treatments.

Olutasidenib is Highly Effective in Certain Patients with Myelodysplastic Syndrome

August 6th 2025

The novel targeted drug olutasidenib has been shown to be effacacious in select patients with MDS.

Study Shows DNA Regulatory Switch Prompts Stem Cells to Give Rise to Blood

July 29th 2025

New study takes a deep dive into how TAF1 operates to promote development of new blood cells.

Molecular Profiling Yields Insights into Glioblastoma

May 14th 2025

Two new tumor profiling studies offer insights into how to classify such brain tumors and how they evolve after treatment.

Clinical Trial Opens for Patients With High-Grade Neuroendocrine Cancer

April 15th 2025

Sylvester Comprehensive Cancer Center has opened a clinical trial for patients with high-grade neuroendocrine cancers evaluating an oncolytic virus.

Viral Mimicry May Enhance Immune Response Against Glioblastomas

March 18th 2025

Scientists from Sylvester Comprehensive Cancer Center have found that targeting ZNF638 can induce an antiviral response in glioblastoma.

Sylvester Study Leads to Updated National Guidelines for Follicular Lymphoma Treatment

March 5th 2025

Sylvester researchers recently published positive data on a new treatment regimen for patients with relapsed or refractory follicular lymphoma.

Biological Age as a Tool to Predict Early-Onset Colorectal Cancer Risk

December 18th 2024

A person’s “biological age” may be a hidden factor in their risk of colorectal cancer before the age of 50.

Some Lung Cancer Disparities Lessen in South Florida

September 4th 2024

Racial/ethnic minorities are often diagnosed with lung cancer at later stages than White patients but that disadvantage is smaller in Hispanic populations.

Study Identifies Biomarker That Could Predict Chemotherapy Benefits for Colon Cancer Patients

July 31st 2024

Steven Chen, PhD, and colleagues identified a 10-gene biomarker that may predict benefit with adjuvant chemotherapy in stage II/III colon cancer.

Dr Estelamari Rodriguez Honored as GRACE Patient Educator of the Year

July 3rd 2024

Estelamari Rodriguez, MD, MPH, is breaking down barriers to care by creating Spanish-language content about lung cancer for patients and caregivers.

Older Adults With Aggressive Blood Cancer Are Responsive to Treatment and Show Prolonged Survival

May 21st 2024

According to a study published in Blood Neoplasia, standard-of-care treatment for acute myeloid leukemia is safe and effective for adults over 80.

Sylvester Brain Tumor Institute Launches to Personalize Brain Cancer Treatment

May 14th 2024

Sylvester Comprehensive Cancer Center at the University of Miami Miller School of Medicine announced the formation of the Sylvester Brain Tumor Institute.

Sylvester Oncologist Contributes to Global Plan to Fight Prostate Cancer

May 7th 2024

Brandon Mahal, MD, of Sylvester Comprehensive Cancer Center, was commissioned to write a collaborative article on prostate cancer for The Lancet.

Studying Endometrial Cancer in Black Women

April 30th 2024

Two new grants from the U.S. Department of Defense will support Sylvester Comprehensive Cancer Center studies of endometrial cancer in Black women.

What If We Could Eliminate a Major Gastric Cancer Risk Factor?

April 24th 2024

A study by Sylvester Comprehensive Cancer Center assessed the outcomes of a community-based effort to test for and eradicate H. pylori, a major risk factor for gastric cancer.

Experimental MDS Drug Appears Beneficial for Some

April 7th 2024

In a new phase 3 clinical trial, imetelstat demonstrated clear advantages for patients who have failed or are ineligible for other therapies.

Sylvester Cancer, NANETS Partner to Present Regional Conference on Multidisciplinary Management of Neuroendocrine Tumors

April 1st 2024

Sylvester Comprehensive Cancer Center and NANETS will present a regional educational conference focusing on neuroendocrine tumors.

Sylvester Appoints Prominent Oncologist-Researcher to Lead Transplantation and Cellular Therapy

March 22nd 2024

Damian Green, MD, will join Sylvester Comprehensive Cancer Center this spring to lead its transplantation and cellular therapy services.

Potential New Treatment for Head and Neck Cancers

March 15th 2024

Some head and neck cancers may respond to the drug olaparib or the combination of olaparib with decitabine.